Jim Tananbaum’s Foresite Capital Recruits Dr. Molly He

In an article on INC42, recently, Foresite Capital hired Dr. Molly He to serve as a venture partner. The healthcare growth equity corporation is expected to benefit from Molly’s extensive expertise in the genomic research and development, and pharmaceutical. The founder of the company, Jim Tananbaum, asserted that Dr. He is one of the revered scientific researchers on matters next-generation sequencing. He went on to say that the entire Foresite Capital team was thrilled to welcome her to the company. Jim Tananbaum contended that her visionary leadership would be an invaluable resource to Foresite Capital, as they seek to expand and diversify the company’s portfolio of transformational corporations. Formerly, Dr. Molly worked for Illumina as a senior director.

At Illumina, Dr. Molly was in charge of global protein reagent improvements. She has also worked for Pacific Biosciences as the chief of protein sciences. Part of her role was to develop protein reagent for the entity’s single molecular real-time sequencing chemistry. According to Biz Journals, earlier in her career, she focused on structural-based design of antibody as well as development of small molecule drugs that target cancer and immune diseases. While accepting her new role, Dr. Molly posited that Foresite Capital had unrivaled reputation in investing in some of the leading healthcare companies.

Over the years, Foresite Capital has been providing emerging healthcare companies with growth capital. The San Francisco-based company focuses on developing and commercializing transformative products that seeks to address the unmet healthcare needs. For the last 20 years, Jim Tananbaum has been building healthcare corporations.

Previously, he co-founded two healthcare investment practices and biopharmaceutical entities. While he was completing his studies at Harvard Medical School, he incorporated a successful corporation, GelTex Pharmaceuticals. This company is credited for bringing two drugs of less than $80 million to the market. Today, these drugs are making $ 1 billion in revenues. After being in operation for a few years, it was acquired for $1.6 billion.

In addition, Tananbaum is affiliated with Sierra Ventures and Prospect Venture Partners II and III. He has also played a pivotal role in the success of Healtheon, Amira Pharmaceuticals, Jazz Pharmaceuticals and Amerigroup. Jim is a graduate of Harvard Medical School, MIT, Harvard Business School, and Yale University. Notably, Tananbaum has sits on the advisory boards of Yale and Harvard-MIT HST program.

See more: https://www.linkedin.com/in/jim-tananbaum-a7562a7/

Leave a Reply

Your email address will not be published. Required fields are marked *